Tim Smith

These data were the conclusion of a case series highlighting the experiences and responses of African American patients with alopecia areata who utilize JAK inhibitors.

This FDA approval makes pz-cel the first single application therapy to receive FDA approval for recessive dystrophic epidermolysis bullosa.

These findings point to a need for evidence-based digital health information access to counter misinformation regarding androgenetic alopecia.

In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.

These data point to the necessity of incorporating disease burden in patient interactions and decision making for those under the age of 18 years.

These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

These data highlight the risk level among certain patients with psoriasis of excessive sun exposure, associated commonly with tanning.

In these findings, the FamilyPso tool was validated for assessing psoriasis burdens on family members in multiple countries.

This study highlights the different sex-related disparities as well as those among older adults with atopic dermatitis.

This discrete choice experiment analysis provides improved understanding of the priorities of patients using teledermatology for psoriasis.

These real-world findings on upadacitinib for atopic dermatitis highlight the drug’s efficacy and survival data among Australian patients.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

Dupilumab's approval marks the first new, targeted therapy for CSU in more than a decade and is the 7th indication for a disease with underlying type 2 inflammation.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

This network meta-analysis compares the relative effectiveness and safety of different monotherapies for patients living with alopecia areata.

The interchangeable designation was granted to CT-P17, a biosimilar to adalimumab (Humira), for inflammatory diseases such as psoriasis.

This systematic review highlights current research on ruxolitinib’s off-label use in dermatology, specifically for conditions such as alopecia and psoriasis.

These data on 5α-reductase inhibitors highlight impacts on patients with benign prostatic hyperplasia or androgenic alopecia.

This analysis demonstrates the effectiveness of methotrexate application via microinfusion in frontal fibrosing alopecia.

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

These data highlight the potential impacts of baricitinib across significant hair-bearing areas involved in alopecia areata.

This retrospective, real-world analysis highlights several notable findings on JAK inhibitor use among patients with alopecia areata.

In our Q1 recap for dermatology, we spotlight clinical trial data, recent updates, and advancements in therapeutic options.

This research highlights the potential of a tripeptide as a topical emollient-based cream for patients with psoriasis.

This review highlights disparities among patients of color in terms of atopic dermatitis prevalence, management, and outcomes in the post-COVID-19 world.

These findings were the result of a new analysis of the inflammatory characteristics associated with the efficacy sustenance of biologic medications for psoriasis.

These findings, while reassuring for JAK inhibitor prescription, nonetheless suggest that VTE-related recommendations for prescriptions should be maintained.

These findings indicate that lower ambient solar radiation is linked with more frequent systemic psoriasis therapy.